Study on BrECADD Therapy for Stage 2 B-IV Hodgkin Lymphoma

Inclusion Criteria

• Adults aged 18 to 60 years with a confirmed diagnosis of classical Hodgkin Lymphoma.
• Must have cancer that shows up on specific scans and have at least one measurable tumor.
• Cancer must be at Stage 2 B with certain risk factors, or Stage III or IV.
• Must be in relatively good health with a performance status score of 2 or less.
• Life expectancy of at least 3 months.
• Women must use effective birth control during treatment and for 6 months after, as the treatment may affect hormonal contraceptives.
• Men must use barrier contraception if their partner is of childbearing potential.
• Must have normal organ and bone marrow function as shown by specific blood tests.
• Must be able to understand and agree to the study requirements and sign a consent form.

Exclusion Criteria

• Have Stage I or IIA Hodgkin Lymphoma.
• Have a different type of Hodgkin Lymphoma called nodular lymphocyte-predominant.
• Have had previous treatment for lymphoma, except for certain types of indolent lymphoma.
• Have uncontrolled heart disease or high blood pressure.
• Have active autoimmune blood disorders.
• Have other serious medical conditions or infections that could interfere with the study.
• Have severe lung disease or nerve damage.
• Have another active cancer or a history of cancer within the last 3 years, except for certain skin or localized cancers.
• Are pregnant or breastfeeding.
• Have active infections like HIV, hepatitis B, or hepatitis C, unless under control.
• Have impaired decision-making ability.
• Have had major surgery within 4 weeks before starting the study.
• Need a live vaccine within 28 days before or during the study.
• Have allergies to any of the study drugs.
• Are participating in another clinical trial.